Martin Meglasson - Net Worth and Insider Trading
Martin Meglasson Net Worth
The estimated net worth of Martin Meglasson is at least $2 Million dollars as of 2024-09-20. Martin Meglasson is the V-P, Discovery Research of Ligand Pharmaceuticals Inc and owns about 17,042 shares of Ligand Pharmaceuticals Inc (LGND) stock worth over $2 Million. Martin Meglasson is also the Chief Scientific Officer of Bellerophon Therapeutics Inc and owns about 1,273 shares of Bellerophon Therapeutics Inc (BLPH) stock worth over $45. Details can be seen in Martin Meglasson's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Martin Meglasson has not made any transactions after 2015-05-20 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Martin Meglasson
Martin Meglasson Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Martin Meglasson owns 2 companies in total, including Bellerophon Therapeutics Inc (BLPH) , and Ligand Pharmaceuticals Inc (LGND) .
Click here to see the complete history of Martin Meglasson’s form 4 insider trades.
Insider Ownership Summary of Martin Meglasson
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| BLPH | Bellerophon Therapeutics Inc | 2015-05-20 | Chief Scientific Officer |
| LGND | Ligand Pharmaceuticals Inc | 2010-05-11 | V-P & Discovery Research |
Martin Meglasson Latest Holdings Summary
Martin Meglasson currently owns a total of 2 stocks. Among these stocks, Martin Meglasson owns 17,042 shares of Ligand Pharmaceuticals Inc (LGND) as of May 11, 2010, with a value of $2 Million and a weighting of 100%. Martin Meglasson also owns 1,273 shares of Bellerophon Therapeutics Inc (BLPH) as of May 20, 2015, with a value of $45 and a weighting of 0%.
Latest Holdings of Martin Meglasson
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| LGND | Ligand Pharmaceuticals Inc | 2010-05-11 | 17,042 | 105.01 | 1,789,580 |
| BLPH | Bellerophon Therapeutics Inc | 2015-05-20 | 1,273 | 0.04 | 45 |
Holding Weightings of Martin Meglasson
Martin Meglasson Form 4 Trading Tracker
According to the SEC Form 4 filings, Martin Meglasson has made a total of 0 transactions in Ligand Pharmaceuticals Inc (LGND) over the past 5 years. The most-recent trade in Ligand Pharmaceuticals Inc is the acquisition of 1,042 shares on May 11, 2010, which cost Martin Meglasson around $10,188.
According to the SEC Form 4 filings, Martin Meglasson has made a total of 0 transactions in Bellerophon Therapeutics Inc (BLPH) over the past 5 years. The most-recent trade in Bellerophon Therapeutics Inc is the acquisition of 47 shares on May 20, 2015, which cost Martin Meglasson around $5,981.
Insider Trading History of Martin Meglasson
- 1
Martin Meglasson Trading Performance
GuruFocus tracks the stock performance after each of Martin Meglasson's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Martin Meglasson is -8.18%. GuruFocus also compares Martin Meglasson's trading performance to market benchmark return within the same time period. The performance of stocks bought by Martin Meglasson within 3 months outperforms 2 times out of 5 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Martin Meglasson's insider trading performs compared to the benchmark.
Performance of Martin Meglasson
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | -1.46 | | | | | |
| Relative Return to S&P 500(%) | -1.01 | | | | | |
Martin Meglasson Ownership Network
Martin Meglasson Owned Company Details
What does Bellerophon Therapeutics Inc do?
Who are the key executives at Bellerophon Therapeutics Inc?
Martin Meglasson is the Chief Scientific Officer of Bellerophon Therapeutics Inc. Other key executives at Bellerophon Therapeutics Inc include 10 percent owner Puissance Life Science Opportunities Fund Vi , VP of Business Operations Parag Suresh Shah , and See Remarks Martin Dekker .
Bellerophon Therapeutics Inc (BLPH) Insider Trades Summary
Over the past 18 months, Martin Meglasson made no insider transaction in Bellerophon Therapeutics Inc (BLPH). Other recent insider transactions involving Bellerophon Therapeutics Inc (BLPH) include a net sale of 694,421 shares made by Puissance Capital Fund (gp) Llc , a net sale of 1,076,841 shares made by Puissance Life Science Opportunities Fund Vi , and a net sale of 9,455 shares made by Bobae Kim .
In summary, during the past 3 months, insiders sold 0 shares of Bellerophon Therapeutics Inc (BLPH) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 1,780,717 shares of Bellerophon Therapeutics Inc (BLPH) were sold and 0 shares were bought by its insiders, resulting in a net sale of 1,780,717 shares.
Bellerophon Therapeutics Inc (BLPH)'s detailed insider trading history can be found in Insider Trading Tracker table.
Bellerophon Therapeutics Inc Insider Transactions
Martin Meglasson Mailing Address
Above is the net worth, insider trading, and ownership report for Martin Meglasson. You might contact Martin Meglasson via mailing address: 53 Frontage Road, Suite 301, Hampton Nj 08827.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
